Skip to search formSkip to main contentSkip to account menu

Aracytin

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cytarabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Progressão de policitemia Vera para leucemia mieloide aguda
Introducao: A Policitemia Vera (PV) e um disturbio clonal caracterizado pela hiperplasia de celulas hematopoieticas, com acumulo… 
Review
2014
Review
2014
Tyrosine Kinase Inhibitors and Interferon
The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the… 
2009
2009
A novel High dose chemotherapy strategy with Bendamustine in Adjunct to Etoposide, Aracytin and Melphalan (BeEAM) Followed by Autologous Stem cell rescue in Resistant/Relapsed Hodgkin and Non-Hodgkin…
Abstract 4351 We designed a phase I study to evaluate the safety and the efficacy of increasing doses of Bendamustine, coupled… 
2008
2008
Reduced expression of hepcidin in patients with myelodysplastic syndrome and myelofibrosis: the causes might be more heterogeneous than in thalassaemia
Baer, M.R., Stewart, C.C., Dodge, R.K., Leget, G., Sule, N., Mrozek, K., Schiffer, C.A., Powell, B.L., Kolitz, J.E., Moore, J.O… 
2008
2008
Fotemustine, Etoposide, Aracytin and Melphalan (FEAM), a Different Conditioning Regimen for Lymphoma Treatment with Autologous Hemopoietic Stem-Cell Transplantation
Introduction . BEAM (carmustine, etoposide, aracytin, melphalan) is a conditioning regimen used in autologous hemopoietic stem… 
2006
2006
MIDAM Regimen (Mylotarg + Intermediaite Dose Aracytin + Mitoxantrone) Is an Effective Combination of Chemo-Immunotherapy for Relapsed/Refractory CD33+ AML Patients.
Introduction: Refractory and relapsed AML patients have very poor outcome. Recently we have described a new combination of chemo… 
2004
2004
A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
Acute myeloid leukemia (AML) predominantly affects older adults, a population with a poor prognosis, due to age, comorbidities… 
2004
2004
Mylotarg 9 mg/m² Combined with Intermediate Dose Aracytin and Mitoxantrone (MIDAM) in Relapsed/Refractory CD33+ Acute Myeloid Leukemia: A Single Center Phase II Experience.
When combined with chemotherapy, Mylotarg is currently used in lower doses, due to the risk of hepatic toxicity and veno… 
1998
1998
Phase I–II Study of Carboplatin with VP16 and Aracytin for Poor-Risk-Acute Leukemia
We conducted a phase I–II trial of escalating dose of carboplatin (CB) 0.750, 0.875, 1000 g/m2 (level 1, 2, 3 respectively) given… 
1991
1991
Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients.
Eighteen acute nonlymphoblastic leukemia patients greater than 60 yr., 12 at diagnosis and 6 in first relapse, were treated with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)